PDCD1 and metastatic malignant neoplasm: Within this changing context, immunotherapy has emerged as a notable breakthrough, especially following the sanctioning of programmed cell death protein 1 (PD-1) inhibitors for the treatment of recurrent or metastatic cancers (12).